Kornimate/medical-research-clean huggingface dataset:
to assess the efficacy of esomeprazole 40 mg once daily in subjects who still had heartburn after receiving rabeprazole

Conditions: Heartburn

Summary: administration of esomeprazole 40 mg to subjects who still had heartburn after receiving rabeprazole 20 mg once daily for 4 to 8 weeks will result in statistically significant improvement of heartburn after 8-week treatment.


Eligibility criteria:
inclusion criteria: * male or female aged 20 years or more * documented history of reflux esophagitis verified by endoscopy in the past, including the grade of los angeles (la) classification (lundell lr et al 1999) before treatment * ongoing (until date of visit 1) treatment with rabeprazole 20 mg, given once daily, for a period of 4 to 8 weeks. the subject must take rabeprazole at least 4 days a week in the past 7 days prior to visit 1. * persisting symptoms of heartburn during the past 7 days prior to visit 1, judged by the investigator(s) as follows: at least 2 days with moderate (i.e. discomfort sufficient to cause interference with normal activities) to severe symptoms (i.e. incapacitating, with inability to perform normal activities) or at least 4 days with symptoms including mild ones (i.e. awareness of sign or symptom, but easily tolerated). * the subject needs to be able to understand and read the official languages of the country. exclusion criteria: * use of other ppis and/or h2ra during rabeprazole treatment * previous use of esomeprazole 40 mg during the 12 weeks before enrolment * current or historical evidence of gastrointestinal pathology * history, signs or symptoms of clinically significant or uncontrolled cardiovascular, pulmonary, renal, endocrine, hematologic, neurologic, psychiatric pancreatic or hepatic disease as judged by the investigator to interfere with the conduct of the study, the interpretation of study results, subject compliance, or the health of the subject during the study. * documented upper gastrointestinal surgery such as gastric resection, vagotomy and/or pyloroplasty, hiatus hernia surgery or fundoplication. note: endoscopic polypectomy, endoscopic mucosal resection, endoscopic submucosal dissection or simple suturing of an ulcer are not exclusion criteria.

Keywords: patients, single
phenotyping patients admitted to hospital with covid-19 infection and identifying prognostic markers

Conditions: Coronavirus; Corona Virus Infection; COVID-19; 2019nCoV; 2019 Novel Coronavirus Infection

Summary: phenotype is an investigator-led, observational cohort study which aims to explore the long-term outcomes of patients with covid-19 infection and to identify potential risk factors and biomarkers that can prognosticate disease severity and trajectory.

in 2019, a novel coronavirus, sars-cov-2 was first identified in wuhan, china. sars-cov-2 infection, denominated covid-19, causes a predominantly respiratory illness, which varies from mild respiratory symptoms to multi-organ failure and death. in march 2020, covid-19 was designated pandemic status and as of may 2020 there have been more than 3.7 million cases reported worldwide and 257,000 deaths attributed. in the uk, covid-19 has caused more than 30,000 deaths to date. although respiratory symptoms are the commonest presentation, numerous systemic complications of covid-19 have been identified, including those affecting the cardiovascular, neurological, gastroenterological, and renal systems. the long-term impact of these complications on survivors and the risk factors for long term sequelae is not presently known. it is likely that increased frailty and psychological sequelae will be significant, which could lead to a persistent reduction in quality of life, as observed in the previous sars pandemic. this cohort study aims to evaluate the respiratory, cardiac, renal and psychological outcomes of patients diagnosed with covid-19 infection and determine the pathophysiological mechanisms that contribute to disease severity and disease burden.

Eligibility criteria:
inclusion criteria * aged 18 years or older * confirmed covid-19 infection (as per national guidelines) * attending follow-up outpatient visit post hospital attendance with covid-19 infection exclusion criteria there are no specific exclusion criteria

Keywords: covid-19 blood phenotyping
differences in postoperative symptoms with four ureteral stents

Conditions: Urinary Stone

Summary: this is a prospective randomized controlled trial designed to assess the differences in postoperative symptoms related to placement of a 6fr percuflex ureteral stents, 6fr tria ureteral stents, 4.8fr percuflex ureteral stents, and 4.8fr tria ureteral stents after ureteroscopy with laser lithotripsy for treatment of upper tract urinary stones. 272 participants will be enrolled and will be on study for up to approximately 10 weeks.

the investigators will compare ureteral stent symptom questionnaire (ussq) scores with each ureteral stent. laser lithotripsy is a surgical procedure performed during stone surgeries. the percuflex ureteral stent and tria ureteral stent are fda approved and clinically used in the united states. a total of 3 clinic visits (i.e., pre-operative visit, the stent removal 1-2 weeks after surgery, and one post-operative visit 3-6 weeks after surgery) in addition to the surgery will be needed for this study. the patient's demographic information and medical background data will be collected from the medical record. the ussq will be administered twice: 1. at the time of stent removal (1-2 weeks after surgery ) (this is standard of care) 2. at the first postoperative follow-up after stent removal (3-6 weeks) (this is the standard of care). the following information will be collected as secondary outcomes: 1. wisqol which will be administered three times. it is uw standard of care for stone patients to complete the wisqol at every clinic visit. 2. er visits documented in patients chart 3. unscheduled clinic follow-up documented in patient chart 4. additional prescriptions for stent related symptoms documented by patient chart 5. stent complications by fluoroscopy or image 6. physician evaluation of the stent. physicians will complete a one page survey at the end of the case evaluating the stent.

Eligibility criteria:
inclusion criteria: * patients with renal or ureteral urinary stones who require endoscopic treatment and stent placement in the outpatient operating room. exclusion criteria: * pregnant patients * patients with transplant kidneys * patients with irreversible coagulopathy * patients with known ureteral stricture disease * non-english speaking, vulnerable patients such as lacking of decision-making capability, prisoner, adult unable to consent, will not be enrolled. * patients with planned staged procedures. * patients who have stent placed before surgery.
hyperglycemia in neurosurgery

Conditions: Hyperglycemia; Postoperative Infection

Summary: poor glycemic control is recognized as a risk factor for postoperative infection. for the neurosurgical patient, postoperative infection can lead to devastating complications such as meningitis, encephalitis and death. neurosurgical patients often receive high doses of medications that increase blood glucose levels such as steroids, placing them at a potentially higher risk for postoperative infection. the purpose of this multisite observational study is to assess the impact of severe intraoperative hyperglycemia as a risk factor for postoperative infection in the neurosurgical patient.

this is a multisite \[3 locations\] prospective observational study of adult patients (18-89 years old) scheduled for elective intracranial (open or endoscopic) procedures that require general anesthesia and a hospital stay of at least 1 day after the surgery. all sites will follow the standard of care clinical protocol for glycemic management that was developed at boston medical center (bmc). laboratory tests will be collected at the discretion of the primary clinician. this observational study does not require any change to routine clinical practice. the following perioperative data (timeframe between pre-procedure clinic visit through post-anesthesia care unit discharge): blood glucose measurements, total insulin dose, total dexamethasone dose, estimated intraoperative blood loss, antibiotic prophylaxis regimen. the patient's electronic medical records data will be reviewed 7 days after the neurosurgical procedure to abstract all available culture data (blood, urine, sputum, csf), available treatment regimen data prescribed for infection (antibiotics), complications from hyperglycemia (diabetic ketoacidosis, hyperglycemic nonketotic coma) or insulin therapy (hypoglycemia episodes). intensive care unit (icu) and hospital length of stay will also be obtained form the medical records. the investigators anticipate finding four groups of patients with regards to intraoperative blood glucose levels and management: 1) patients with no episodes of severe intraoperative hyperglycemia, 2) patients with intraoperative hyperglycemia who received insulin treatment, 3) patients with intraoperative hyperglycemia who did not receive insulin treatment and 4) patients with no available laboratory data.

Eligibility criteria:
inclusion criteria: * adult patients scheduled for elective intracranial (open surgical or endoscopic) intervention * general anesthesia * hospital stay of at least 1 day post-procedure exclusion criteria: * diagnosis of infection (local or systemic) in preoperative period * emergency procedures

Keywords: intraoperative hyperglycemia postoperative infection neurosurgical patient open surgical intracranial intervention endoscopic intracranial intervention
the safety and tolerability of comp360 in participants with post-traumatic stress disorder

Conditions: Post Traumatic Stress Disorder

Summary: the safety and tolerability of comp360 in participants with post-traumatic stress disorder

the safety and tolerability of comp360 administered under supportive conditions in participants with post-traumatic stress disorder

Eligibility criteria:
key inclusion criteria: * meet dsm-5 criteria for current ptsd resulting from a trauma experienced during adulthood measured via the pcl-5 in combination with the lec-5 at screening * meet dsm-5 criteria for current ptsd resulting from a trauma experienced during adulthood as assessed by the caps, with a minimum score of 25 at baseline * able to identify a next of kin who is willing and able to be reached by the investigators in case of emergency * have successfully discontinued all prohibited medications at least two weeks prior to baseline visit. for fluoxetine (prozac), immediate cessation at screening period visit 1a followed by at least four weeks of run-in will be required prior to baseline key exclusion criteria: * current or past history of schizophrenia, schizoaffective disorder or any other form of psychotic disorder, obsessive compulsive disorder, personality disorders, bipolar disorder, or any other significant disorder as assessed by clinician judgement and a structured clinical interview (mini 7.0.2) * diagnosis of complex ptsd according to clinician judgement * borderline personality disorder as demonstrated by both the mclean screening instrument for borderline personality disorder (msi- bpd) score ≥ 7 and clinical confirmation of diagnosis by the study clinician and medical monitor * significant suicide risk as defined by (1) suicidal ideation as endorsed on items 4 or 5 on the c-ssrs within the past year, during screening or at baseline, or; (2) suicidal behaviours within the past year, or; (3) history of serious suicide attempt that required a rescuing medical intervention, or; (4) clinical assessment of significant suicidal risk during participant interview * current (within the last year) alcohol or substance use disorder as informed by dsm-5 assessed via the mini 7.0.2 at screening * other personal circumstances and behaviour judged to be incompatible with establishment of rapport or safe exposure to psilocybin * exposure to 3,4-methylenedioxymethamphetamine (mdma), psilocybin, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide (lsd), or peyote in the past year * primary diagnosis of major depressive disorder within 6 months of study entry * exposure to a traumatic experience in the past 3 months * significant childhood physical or sexual abuse based on clinician judgment with the use of ctq * enrolment in a psychological therapy programme that will not remain stable for the duration of the study. psychological therapies cannot have been initiated within 21 days of baseline

Keywords: psilocybin comp360 compass ptsd post traumatic stress disorder
exercise type that faster reduces postprandial glycemia.

Conditions: Glucose, High Blood; Exercise-Induced Hyperinsulinism

Summary: it is well established that a bout of 50 min of continuous moderate intensity exercise, improves insulin sensitivity up to 48 hours after the bout. however, it is less well known, what is the exercise type more efficient to buffer the elevations in blood glucose elicited by carbohydrate ingestion. the purpose of this study is to elucidate if intervalic exercise is superior to continous on improving postprandial glycemic control.

carbohydrate oxidation, glucose and insulin blood concentrations, isotopically measured rate of appearance of endogenous and exogenous glucose will be measured in 4 ocassions. participants will undergo in a cross-over randomized fashion the following trials: 1. exercise pedalling during 50 min at 60% of their vo2max followed by an oral glucose tolerance test (ogtt). 2. exercise pedalling during 50 min in a hot environment (33ºc) at 60% of their vo2max followed by an oral glucose tolerance test (ogtt). 3. exercise pedalling during 50 min using intervalic bouts averaging 60% of vo2max followed by an oral glucose tolerance test (ogtt). 4. no exercise, followed by an oral glucose tolerance test (ogtt).

Eligibility criteria:
inclusion criteria: * participant must be capable and willing to provide consent, understand, instructions and protocols. * minimal fitness level to be able to complete 50 min of continous exercise at a moderate intensity. exclusion criteria: * smokers * pregnancy * any non-controlled medical condition which could influence results or could be worsened by exercise
effects of budesonide & budesonide/formoterol on smoking asthmatic subjects

Conditions: Asthma

Summary: a reduced response to inhaled corticosteroids (ics) has been reported in smoking compared to non-smoking asthmatic patients. however, the comparative response to other currently prescribed medications such as combination therapy of long-acting beta agonists and ics remain to be further evaluated. no significant differences were found between our group of subjects in regard to changes in asthma control pulmonary function and airway inflammation following budesonide or the association of budesonide with formoterol for a period of 2 months. this should be further explored in larger groups of subjects.


Eligibility criteria:
inclusion criteria: * asthmatic non-smokers or ex-smokers (less than 10 pack/years) * asthmatic smokers (more than 5 cigarettes a day and more than 5 pack/years * fev1 greater than 70% * no more than 3 doses of rescue medication (bronchodilator) per day exclusion criteria: * mentally or legally incapacitated thus preventing informed consent from being obtained * other pulmonary disorder * history of upper respiratory tract infection in the last month * pregnant or lactating women
role of18f-fdg pet-ct for assessing and predicting response to daratumumab and for prognosis with multiple myeloma

Conditions: Multiple Myeloma

Summary: positron emission tomography - computed tomography (pet-ct) using fluorine-18 fluorodeoxyglucose is a functional imaging diagnostic tool which is widely used in several neoplastic conditions, at initial staging, for restaging in suspected disease relapse and for assessing the response to treatment. most patients with multiple myeloma (mm) exhibit a high-glycolytic activity rate and therefore they are fog-avid, especially at the disease relapse. the priceless value of 18f-fog pet-ct in the therapeutic assessment for several treatment schemes, including asct, has been highlighted by several studies: particularly, the occurrence of negative pet-ct after a double asct in mm patients with clinical complete response or very good partial response positively correlates with favourable pfs and overall survival (os). likewise, persistence of 18f-fdg avid disease in mm patients achieving a clinical complete response constitutes a poor prognostic factor. primary objective of this prospective, observational, non-pharmacological, multicentric study is to evaluate the role of 18f-fdg pet-ct for assessing early response after 6 months of treatment with daratumumab in patients with .relapsed/refractory mm.


Eligibility criteria:
inclusion criteria: * patients with refractory multiple myeloma who relapsed after therapy with daratumumab in combination with dexamethasone + bortezomib or dexamethasone + lenalidomide; * patients capable of expressing informed consent. exclusion criteria: * patients with clinical contraindications to the administration of daratumumab; * patients with coexisting non-hematological neoplastic condition; * patients\< 18 years; * patients uncapable of expressing informed consent.
clinical evaluation of t.r.u.e. test in children and adolescents

Conditions: Dermatitis, Contact

Summary: open, prospective, single-site, non-randomized study of the efficacy and safety of t.r.u.e. test allergens in children and adolescents ages 6-18.

three t.r.u.e. test panels (1.1, 2.1 and 3.1) containing 28 allergens and a negative control will be applied to the skin on the subject's back and worn for approximately 48 hours. patch test site skin reactions will be evaluated at days 2, 3 (+1), 7 and 21 following panel application

Eligibility criteria:
inclusion criteria: * symptoms and history potentially consistent with allergic contact dermatitis based on symptoms and clinical history (i.e., subjects are visiting the clinic/physician to diagnose, treat or resolve this condition). * children and adolescents 6 to 18 years of age, and in general good health. * adolescent females 15 years of age or older (or with menarche) must consent to a urine pregnancy test; urine test results must be negative for study inclusion. * informed consent must be signed and understood by subject. if underage, informed consent must be signed and understood by parent or legal guardian, consistent with all institutional, local and national regulations. exclusion criteria: * topical corticosteroid treatment during the last 7 days on or near the test area. * systemic treatment with corticosteroids or other immunosuppressive during the last 7 days. * subjects currently receiving (or received during the previous 3 weeks) other investigational drugs, treatments or devices, or participating in another clinical study. * treatment with ultraviolet (uv) light (including tanning) during the previous 3 weeks. * acute dermatitis outbreak or dermatitis on or near the test area on the back. * subjects unable to comply with activity restrictions (e.g., protecting test panels from excess moisture due to showering or vigorous activity). * subjects unable or unwilling to comply with multiple return visits. * female subjects 15 years of age (or with onset of menarche) and older unable to consent to a urine pregnancy test, or those with a positive pregnancy test.

Keywords: allergic contact dermatitis contact allergy type iv children true test
anger control training for youth with tourette syndrome

Conditions: Tourette Syndrome; Chronic Tic Disorder; Oppositional Defiant Disorder; ADHD

Summary: this is a clinical study of a cognitive-behavioral therapy known as anger control training in adolescents with tourette syndrome and explosive, disruptive behavior. act is compared to treatment as usual (tau) in a randomized clinical trial.

this is a randomized controlled study of a cognitive-behavioral, anger control training (act) in adolescents with tourette syndrome (ts) complicated by disruptive behavior. disruptive behaviors in ts may take numerous forms including noncompliance, anger outbursts, and physical aggression. anger outbursts in ts have been described as rage attacks or rage storms due to their high intensity and unpredictability in response to minimal provocation. whether these behaviors are part of ts, related to comorbid conditions, or due to the burden of chronic illness is not clear. nevertheless, these disruptive behaviors can result in significant functional impairment and often require clinical attention. the purpose of the act intervention is to improve the explosive and noncompliant behavior in adolescents with ts by enhancing affect regulation and social problem-solving skills. the treatment is based on anger control training which has been empirically supported for reducing aggressive behaviors and improving social functioning in aggressive youths. the primary outcome measures include the parent-rated oppositional defiant scale and the clinicians global improvement score assessed by a clinician blind to treatment assignment.

Eligibility criteria:
inclusion criteria: 1. boys and girls, 11 to 16 years of age. 2. diagnosis of tourette syndrome (ts) or chronic tic disorder (ctd). 3. significant level of disruptive behavior exclusion criteria: 1. current diagnosis of severe major depression, bipolar disorder, pervasive developmental disorder, or psychotic disorder. 2. significant medical condition such as heart disease, hypertension, liver or renal failure, pulmonary disease, seizure disorder that may require more pressing treatment. 3. initiation or discontinuation of a psychotropic medication treatment within six weeks of enrollment in the study

Keywords: anger control training cognitive behavioral therapy behavior therapy tourette syndrome randomized trial anger aggression